Form 4: Spyre Therapeutics Director Receives Stock Option Grant
Statement of Changes in Beneficial Ownership
Fairmount Funds Management's Tomas Kiselak was granted 8,026 stock options in Spyre Therapeutics, Inc. as part of his board service.
Summary
- Tomas Kiselak, a director at Spyre Therapeutics and Managing Member of Fairmount Funds Management, received a grant of 8,026 stock options.
- The options have an exercise price of $72.51 per share.
- The options are set to vest on the earlier of May 27, 2027, or the date of the 2027 annual stockholders meeting.
- Mr. Kiselak holds these options for the benefit of investment vehicles managed by Fairmount Funds Management.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial health.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- None identified in this filing.
Risks
- Vesting is subject to the director's continuous service to the issuer through the vesting date.
Future Outlook
The options vest in one year, contingent upon continued board service.
Management Comments
- Mr. Kiselak disclaims beneficial ownership of the option and underlying common stock, except to the extent of his pecuniary interest therein, as he is obligated to turn over proceeds to the Fairmount Fund.
Industry Context
StockSavvy.ai notes that equity grants to board members are standard corporate governance practice in the biotechnology sector to ensure alignment between leadership and shareholders.
Comparison to Industry Standards
- The grant of stock options to non-executive directors is consistent with standard compensation packages for board members in mid-cap biotech firms.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Grant of 8,026 stock options to director Tomas Kiselak. | 05/27/2026 | Standard alignment of director incentives. |
Related Party Transactions
- The reporting person holds the options for the benefit of investment vehicles managed by Fairmount Funds Management LLC.
Stakeholder Impact
- Minimal impact on shareholders as this is a standard equity compensation grant.
Next Steps
- Vesting of options on May 27, 2027.
Key Dates
| Date | Description |
|---|---|
| 05/27/2026 | Date of the option grant transaction. |
| 05/29/2026 | Date the Form 4 was filed with the SEC. |
| 05/27/2027 | Vesting date for the granted stock options. |
| 05/27/2036 | Expiration date of the stock options. |
Keywords
Spyre Therapeutics, SYRE, Form 4, Insider Trading, Stock Options, Fairmount Funds
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.